US EditionPublished • loading... • Updated
After year of triumph, Insmed stumbles with chronic rhinosinusitis fail, brings in new asset
Summary by endpoints.news
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
After year of triumph, Insmed stumbles with chronic rhinosinusitis fail, brings in new asset
Insmed said it is discontinuing work on Brinsupri in a form of chronic rhinosinusitis after the inflammation drug failed a Phase 2b study. The Bridgewater, NJ-based biotech also said Wednesday it's bringing in an old ...
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
